IMR Press / RCM / Volume 3 / Issue 4 / pii/1561516719907-1594449160

Reviews in Cardiovascular Medicine (RCM) is published by IMR Press from Volume 19 Issue 1 (2018). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with MedReviews, LLC.

Open Access Review
Current Anticoagulation Options in Percutaneous Intervention: Designing Patient-Specific Strategies
Show Less
1 Section of Cardiology, University of Chicago, Chicago, IL
Rev. Cardiovasc. Med. 2002, 3(4), 176–182;
Published: 30 December 2002
Abstract
Anticoagulation during percutaneous coronary intervention is critical to prevent abrupt and subacute closure. Although heparin has been the primary anticoagulant used for this purpose, a number of new drugs are now available. Low molecular weight heparin (LMWH) offers some advantages over unfractionated heparin, and clinical trials have shown its superiority. However, the longer half-life and lack of monitoring of LMWH make its use more difficult. The direct thrombin inhibitors also have been shown to have advantages in the treatment of patients with heparin-induced thrombocytopenia.
Keywords
Percutaneous coronary intervention
Anticoagulants
Thrombin inhibitors
Heparin
Low molecular weight heparin
Share
Back to top